Skip to main content
EWTX
NASDAQ Life Sciences

Edgewise Swings to $1.17B Profit on Sevasemten Sale, $1.74B Cash, Phase 3 HCM Trial by Year-End

Tom Rudovsky · Reported by PR Newswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$37.51
Mkt Cap
$4.074B
52W Low
$16.7
52W High
$48.51
52W Position info
125% above low
Off High info
23% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

EWTX has more than doubled off its 52-week low of $16.7.

Summary

Edgewise posted Q3 2026 net income of $1,166.2 million, or $10.71 per basic share, versus a $40.7 million loss a year ago, almost entirely from the $1.348 billion gain on the July sale of its sevasemten muscular dystrophy business to Servier. The company collected $1.396 billion in upfront cash at closing, lifting cash, cash equivalents and marketable securities to roughly $1,743.9 million as of September 30 — a balance that dwarfs the operating burn of $46.1 million for the quarter. R&D fell to $31.6 million from $37.5 million on lower sevasemten costs, while G&A rose to $14.6 million from $9.4 million as headcount expanded. On the pipeline, management said the Phase 3 trial of EDG-7500 in obstructive and nonobstructive HCM remains on track to start by year-end 2026, and the first patient has been dosed in the Phase 2 EQUINOX-HFpEF study of EDG-15400. The profit is a one-time transaction gain, not operating earnings — the real story is the cash pile funding two cardiovascular programs and the imminent Phase 3 start.

At the time of this announcement, EWTX was trading at $37.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $16.70 to $48.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

EWTX - Latest Insights

EWTX
Nov 06, 2026, 11:47 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $43.18
Real-time Price: $45.93 info
Change: +$2.76 (+6%) info
Market Cap: $5.029B info
EWTX
Aug 06, 2026, 8:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $44.95
Real-time Price: $45.93 info
Change: +$0.980 (+2%) info
Market Cap: $5.029B info
EWTX
Aug 06, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $44.95
Real-time Price: $45.93 info
Change: +$0.980 (+2%) info
Market Cap: $5.029B info
EWTX
Jul 16, 2026, 8:01 AM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $39.23
Real-time Price: $45.93 info
Change: +$6.70 (+17%) info
Market Cap: $5.029B info
EWTX
Jun 01, 2026, 8:51 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $43.15
Real-time Price: $45.93 info
Change: +$2.78 (+6%) info
Market Cap: $5.029B info